Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

ARS Pharmaceuticals (SPRY) EBIAT (2021 - 2025)

ARS Pharmaceuticals' EBIAT history spans 5 years, with the latest figure at -$41.3 million for Q4 2025.

  • For Q4 2025, EBIAT fell 182.76% year-over-year to -$41.3 million; the TTM value through Dec 2025 reached -$171.3 million, down 2241.76%, while the annual FY2025 figure was -$171.3 million, 2241.76% down from the prior year.
  • EBIAT for Q4 2025 was -$41.3 million at ARS Pharmaceuticals, up from -$51.2 million in the prior quarter.
  • Across five years, EBIAT topped out at $49.9 million in Q4 2024 and bottomed at -$51.2 million in Q3 2025.
  • The 5-year median for EBIAT is -$14.9 million (2023), against an average of -$13.6 million.
  • The largest annual shift saw EBIAT soared 796.62% in 2024 before it crashed 258.6% in 2025.
  • A 5-year view of EBIAT shows it stood at $45.8 million in 2021, then tumbled by 131.52% to -$14.4 million in 2022, then skyrocketed by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then crashed by 182.76% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EBIAT are -$41.3 million (Q4 2025), -$51.2 million (Q3 2025), and -$44.9 million (Q2 2025).